Biaryl diacid inhibitors of human s-PLA2 with anti-inflammatory activity

Bioorganic and Medicinal Chemistry

Volumn 8, Issue 5, 2000, Pages 1087-1109

  Springer, Dane M ^a   Luh, Bing Yu ^a   Bronson, Joanne J ^a   McElhone, Katharine E ^a   Mansuri, Muzammil M ^a   Gregor, Kurt R ^b   Nettleton, David O ^b   Stanley, Paul L ^b   Tramposch, Kenneth M ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHALENYL)METHOXY [1,1' BIPHENYL] 6,3' DICARBOXYLIC ACID; 2 [(3,4 BISPENTYLOXY)PHENYL]METHOXY 3' CARBOXY [1,1' BIPHENYL] 6 ACETIC ACID; 3' CARBOXY 2 [(1,2,3,4 TETRAHYDRO 1,1,4,4 TETRAMETHYL) 7 ANTHRACENYL] [1,1' BIPHENYL] 6 ACETIC ACID; 3' CARBOXY 2 [(5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHALENYL) 1 PROPENYL] [1,1' BIPHENYL] 6 ACETIC ACID; 3' CARBOXY 2 [4 DECYLOXYPHENYL]METHOXY [1,1' BIPHENYL] 6 ACETIC ACID; 4 (3 CARBOXYPHENYL) 3,7 DIMETHYL 9 (2,6,6 TRIMETHYL 1 CYCLOHEXENYL) 2,4,6,8 NONATETRAENOIC ACID; ACETOACETIC ACID DERIVATIVE; DICARBOXYLIC ACID DERIVATIVE; LONAPALENE; PHOSPHOLIPASE A2 INHIBITOR; PROPIONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD PLATELETS; DICARBOXYLIC ACIDS; ENZYME INHIBITORS; HUMANS; MICE; PHOSPHOLIPASES A; SPECTRUM ANALYSIS;

ANIMALIA;

EID: 0034044940     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(00)00047-X     Document Type: Article

References (71)

1. (a) Davies, P.; MacIntyre, D. E. In Inflammation: Basic Principles and Clinical Correlates, 2nd ed.; Gallin, J. I.; Goldstein, I. M.; Snyderman, R., Eds.; Raven Press: New York, 1992; pp 123-138.
2. (b) Lam, B. K.; Austen, K. F. In Inflammation: Basic Principles and Clinical Correlates, 2nd ed.; Gallin, J. I.; Goldstein, I. M.; Snyderman, R., Eds.; Raven Press: New York, 1992; pp 139-148.
3. (c) Zimmerman, G. A.; Prescott, S. M., McIntyre, T. M. In Inflammation: Basic Principles and Clinical Correlates, 2nd ed.; Gallin, J. I.; Goldstein, I. M.; Snyderman, R., Eds.; Raven Press: New York, 1992; pp 149-176.
4. (d) Pruzanski, W.; Vadas, P. Immunology Today 1991, 12, 143.
5. (e) Vadas, P.; Pruzanski, W. Lab. Invest. 1986, 55, 391.
6. Henderson W.R. Jr. Am. Rev. Respir. Dis. 143:1991;S86.
7. Pruzanski W., Vadas P. J. Rheumatol. 15:1988;1601.
8. Forster S., Ilderton E., Norris J.F., Summerly R., Yardley H.J. Br. J. Dermatol. 112:1985;135.
9. Nevalainen T. Scand. J. Gastroenterol. 15:1980;641.
10. (a) Gregson, N. A. Biochem. Soc. Trans. 1989, 17, 280.
11. (b) Trotter, J.; Smith, M. A. Clin. Biol. Res. 1984, 146, 55.
12. Vadas P.J. Lab. Clin. Med. 104:1984;873-881.
13. Ford D.A., Hazen S.L., Saffitz J.E., Gross R.W.J. Clin. Invest. 88:1991;331.
14. Van den Bosch H. Biochim. Biophys. Acta. 604:1980;191.
15. Axelrod, J. Chem. Senses 1989, 1, 1; Brand, J. G. Ed.; Dekker: New York.
16. Di Marzo V., Galadari S.H.I., Tippins J.R., Morris H.R. Life Sci. 49:1991;247.
17. Arita H., Hanasaka K., Nakano T., Oka S., Teroka H., Matsumoto K. J. Biol. Chem. 266:1991;19139.
18. Gupta C. Proc. Soc. Exp. Biol. Med. 188:1988;489.
19. Fry M.R., Ghosh S.S., East J.M., Franson R.C. Biology Of Reproduction. 47:1992;751.
20. Elsbach P., Weiss J. Biochem. Biophys. Acta. 947:1988;29.
21. Regelson W., Franson R. Ann. N.Y. Acad. Sci. 621:1991;262.
22. (a) Clark, J. D.; Milona, N.; Knopf, J. L. Proc. Natl. Acad. Sci. USA 1990, 87, 7708.
23. (b) Kramer, R. M.; Roberts, E. F.; Manetta, J.; Putnam, J. E. J. Biol. Chem. 1991, 266, 5268.
24. (c) Clark, J. D.; Lin, L.-L.; Kriz, R. W.; Ramesha, C. S.; Sultzman, L. A.; Lin, A. Y.; Milona, N.; Knopf, J. L. Cell 1991, 65, 1043.
25. (d) Sharp, J. D.; White, D. L.; Chiou, X. G.; Goodson, T.; Gamboa, G. C.; McClure, D.; Burgett, S.; Hoskins, J.; Skatrud, P. L.; Sportsman, J. R.; Becker, G. W.; Kang, L.H.; Roberts, E. F.; Kramer, R. M. J. Biol. Chem. 1991, 266, 14850.
26. (a) Hazen, S. L.; Hall, C. R.; Ford, D. A.; Gross, R. W. J. Clin. Invest. 1993, 91, 2513.
27. (b) Hazen, S. L.; Gross, R. W. Biochem. J. 1991, 280, 581.
28. Nishijima J., Okamoto M., Ogawa M., Kosaki G., Yamano T. J. Biochem. 94:1983;137.
29. (a) Hara, S.; Kudo, I.; Chang, H. W.; Matsuta, K.; Miyamoto, T.; Inoue, K. J. Biochem. 1989, 105, 395.
30. (b) Seilhamer, J. J.; Pruzanski, W.; Vadas, P.; Plant, S.; Miller, J. A.; Kloss, J.; Johnson, L. K. J. Biol. Chem. 1989, 264, 5335.
31. (c) Kramer, R. M.; Hession, C.; Johansen, B.; Hayes, G.; McGray, P.; Chow, E. P.; Tizard, R.; Pepinsky, R. B. J. Biol. Chem. 1989, 264, 5768.
32. (a) Wery, J.-P.; Schevitz, R. W.; Clawson, D. K.; Bobbitt, J. L.; Dow, E. R.; Gamboa, G.; Goodson, Jr., T.; Hermann, H. B.; Kramer, R. M.; McClure, D. B.; Mihelich, E. D.; Putnam, J. E.; Sharp, J. D.; Stark, D. H.; Teater, C.; Warrick, M. W.; Jones, N. D. Nature 1991, 352, 79.
33. (b) Scott, D. L.; White, S. P.; Browning, J. L.; Rosa, J. J.; Gelb, M. H.; Sigler, P. B. Science 1991, 254, 1007.
34. 2 inhibitors; see: Schevitz, R. W.; Bach, N. J.; Carlson, D. G.; Chirgadze, N. Y.; Clawson, D. K.; Dillard, R. D.; Draheim, S. E.; Hartley, R. W.; Jones, N. D.; Mihelich, E. D.; Olkowski, J. L.; Snyder, D. W.; Sommers, C.; Wery, J.-P. Nature Structural Biology 1995, 2, 458.
35. (a) Jain, M. K.; Ghomaschi, F.; Yu, B.-Z.; Bayburt, T.; Murphy, D.; Houck, D.; Brownell, J.; Reid, J. C.; Solowiej, J. E.; Wong, S.-M.; Mocek, U.; Jarrell, R.; Sasser, M.; Gelb, M. H. J. Med. Chem. 1992, 35, 3584.
36. (b) Gelb, M. H.; Jain, M. K.; Berg, O. Bioorg. Med. Chem. Lett. 1992, 2, 1335.
37. (c) Yu, L.; Dennis, E. A. Bioorg. Med. Chem. Lett. 1992, 2, 1343.
38. (d) For general comments regarding lipase interactions with organized lipid surfaces see: Blow, D. Nature 1991, 351, 444.
39. For examples see: (a) Musser, J. H.; Kreft, A. F.; Failli, A. A.; Demerson, C. A.; Shah, U. S.; Nelson, J. A. International Patent Publication 1991, WO91/06537.
40. (b) Failli, A. A.; Kreft, A. F.; Musser, J. H.; Banker, A. L.; Nelson, J. A.; Shah, U. S. US Patent 1991, 5,071,988.
41. (c) Djuric, S. W.; Haack, R. A.; Miyashiro, J. M. International Patent Publication, 1992, WO92/21644.
42. (d) Tramposch, K. M.; Steiner, S. A.; Stanley, P. L.; Nettleton, D. O.; Franson, R. C.; Lewin, A. H.; Carroll, F. I. Biochem. Biophys. Res. Commun. 1992, 189, 272.
43. (e) Kohler, T.; Heinisch, M.; Kirchner, M.; Peinhardt, G.; Hirschelmann, R.; Nuhn, P. Biochemical Pharmacology 1992, 44, 805.
44. (f) LeMahieu, R. A.; Carson, M.; Han, R.-J.; Madison, V. S.; Hope, W. C.; Chen, T.; Morgan, D. W.; Hendrickson, H. S. J. Med. Chem. 1993, 36, 3029.
45. (g) Beaton, H. G.; Bennion, C.; Connolly, S.; Cook, A. R.; Gensmantel, N. P.; Hallam, C.; Hardy, K.; Hitchin, B.; Jackson, C. G.; Robinson, D. H. J. Med. Chem. 1994, 37, 557.
46. (h) Carson, M.; Han, R.-J.; LeMahieu, R. A.; Madison, V. S. US Patent 1994, 5,298,652.
47. (i) Pisabarro, M. T.; Ortiz, A. R.; Palomer, A.; Cabre, F.; Garcia, L.; Wade, R. C.; Gago, F.; Mauleon, D.; Carganico, G. J. Med. Chem. 1994, 37, 337.
48. (j) Wheeler, T. N.; Blanchard, S. G.; Andrews, R. C.; Fang, F.; Gray-Nunez, Y.; Harris, C. O.; Lambert, M. H.; Mehrotra, M. M.; Parks, D. J.; Ray, J. A.; Smalley, Jr., T. L. J. Med. Chem. 1994, 37, 4118.
49. (k) Potts, B. C. M.; Faulkner, D. J. J. Nat. Prod. 1992, 55, 1701.
50. (l) Tanaka, K.; Matsutani, S.; Kanda, A.; Kato, T.; Yoshida, T. J. Antibiotics 1994, 47, 631.
51. (m) Barnette, M. S.; Rush, J.; Marshall, L. A.; Foley, J. J.; Schmidt, D. B.; Sarau, H. M. Biochem. Pharmacol. 1994, 47, 1661.
52. (n) Carganico, G.; Mauelon, D.; Garcia, M. L. International Patent Publication 1993, WO93/21211.
53. (o) Marki, F.; Breitenstein, W.; Beriger, E.; Bernasconi, R.; Caravatti, G.; Francis, J. E.; Paioni, R.; Wehrli, H. U.; Wiederkehr, R. Agents Actions 1993, 38, 202.
54. (p) Pruzanski, W.; Greenwald, R. A.; Street, I. P.; Laliberte, F.; Stefanski, E.; Vadas, P. Biochem. Pharmacol. 1992, 44, 1165.
55. (q) Garst, M. E. Curr. Opin. Ther. Pat. 1992, 400.
56. (r) Schiehser, G. A.; Von Burg, G. F. US Patent 1991, 5,070207.
57. (s) Marshall, L. A.; Steiner, K. E.; Schiehser, G. A. US Patent 1990, 4,933,365.
58. (a) Burke, J. R.; Gregor, K. R.; Tramposch, K. M. J. Biol. Chem. 1995, 270, 274.
59. (b) For a complete discussion of the 'scooting-mode' assay see: Gelb, M. H.; Berg, O.; Jain, M. K. Curr. Opin. Struct. Biol. 1991, 1, 836.
60. 2 Inhibitors. US Patent 1995, 5,391,817.
61. Kessar S.V., Gupta Y.P., Mohammad T., Khurana A., Sawal K.K. Heterocycles. 22:1984;2723.
62. 2BBr resulted in the loss of the olefin, with retention of the methoxy group. (It is possible that intramolecular Friedel-Crafts cyclization of the unsaturated ester occurred to give products containing a fluorene nucleus, but this has not been rigorously determined.).
63. 2 isolated from human synovial fluid; Marshall, L. A.; Bauer, J.; Sung, M. L.; Chang, J. Y. J. Rheumatol. 1991, 18, 59), and 3.2 μM against the non-pancreatic enzyme isolated from human polymorphonuclear leukocytes (Marki, F.; Breitenstein, W.; Beriger, E.; Bernasconi, R.; Caravatti, G.; Francis, J. E.; Paioni, R.; Wehrli, H. U.; Wiederkehr, R. Agents Actions 1993, 38, 202.
64. 2 isolated from human synovial fluid; Marshall, L. A.; Bauer, J.; Sung, M. L.; Chang, J. Y. J. Rheumatol. 1991, 18, 59), and 3.2 μM against the non-pancreatic enzyme isolated from human polymorphonuclear leukocytes (Marki, F.; Breitenstein, W.; Beriger, E.; Bernasconi, R.; Caravatti, G.; Francis, J. E.; Paioni, R.; Wehrli, H. U.; Wiederkehr, R. Agents Actions 1993, 38, 202.
65. (a) Tramposch, K. M.; Chilton, F. H.; Stanley, P. L.; Franson, R. C.; Havens, M. B.; Nettleton, D. O.; Davern, L. D.; Darling, I. M.; Bonney, R. J. J. Pharmacol. Expt. Therapeut. 1994, 271, 852.
66. (b) Stanley, P. L.; Steiner, S.; Havens, M.; Tramposch, K. M. Skin Pharmacol. 1991, 4, 262.
67. Bradley P.P., Priebat D.A., Christensen R.D., Rothstein G. J. Invest. Derm. 78:1982;206.
68. The compounds tested in the chronic inflammation in vivo assay (2, 4, 28, 36b, 36i) were not evaluated as potential inhibitors of MPO in a control experiment. Thus, the possibility exists that some (or all) of the in vivo activity reported for these compounds in the tables is a consequence of direct inhibition of the enzyme marker MPO rather than a reflection of reduced influx of neutrophils (PMNs). However, animals treated with compound 28 had significant, dose-dependent ear weight reductions that paralleled the measured reduction of myeloperoxidase activity. This implies that the drug is reducing general hyperplasia (and inflammation), and that it is not acting simply as a MPO inhibitor. Many other structurally similar (but non-biaryl) compounds were evaluated in the chronic assay for both ear weight reduction and inhibition of MPO activity. The compounds tested almost always displayed ear weight reductions that paralleled the measured reduction of myeloperoxidase activity.
69. 2), although other explanations are possible.
70. Saa J.M.et al. J. Org. Chem. 57:1992;678.
71. Dawson M.I., Hobbs P.D., Dorsky A., Morimoto H. J. Labelled Compounds and Radiopharmaceuticals. 28:1990;89.